In a filing, Avidity Biosciences Inc revealed its Chief Program Officer Gallagher Kathleen P. unloaded Company’s shares for reported $0.19 million on Feb 03 ’25. In the deal valued at $32.16 per share,5,875 shares were sold. As a result of this transaction, Gallagher Kathleen P. now holds 50,554 shares worth roughly $ 1.63 million.
Then, KATHLEEN GALLAGHER bought 17,625 shares, generating $580,391 in total proceeds.
Before that, LEVIN ARTHUR A sold 1,872 shares. Avidity Biosciences Inc shares valued at $53,537 were divested by the Director at a price of $28.60 per share. As a result of the transaction, LEVIN ARTHUR A now holds 12,958 shares, worth roughly $0.42 million.
H.C. Wainwright initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on December 20, 2024; the price target was $72. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late November with a ‘”an Outperform”‘ rating. Goldman began covering RNA with “Buy” recommendation on September 24, 2024. Barclays started covering the stock on August 28, 2024. It rated RNA as “an Overweight”.
Price Performance Review of RNA
On Friday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -2.15% to $32.31. Over the last five days, the stock has lost -7.47%. Avidity Biosciences Inc shares have risen nearly 11.11% since the year began. Nevertheless, the stocks have risen 143.48% over the past one year. While a 52-week high of $56.00 was reached on 02/07/25, a 52-week low of $13.17 was recorded on 01/14/25. SMA at 50 days reached $32.17, while 200 days put it at $38.40.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 30.96, which if violated will result in even more drops to 29.60. On the upside, there is a resistance level at 33.85. A further resistance level may holdings at 35.38. The Relative Strength Index (RSI) on the 14-day chart is 48.91, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.82, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 55.61%. Stochastics %K at 48.46% indicates the stock is a holding.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-01-31, dropping by -0.73 million shares to a total of 14.95 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 15.68 million shares. There was a decline of -4.91%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 03, 2024 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
